Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
Beamion LUNG-3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- NCT07195695 ↗
- Recruiting
- Boehringer Ingelheim
- Focused
We haven't built an HCP commentary report on Beamion LUNG-3 (zongertinib in resected stage II-IIIB NSCLC harboring HER2 TKD mutations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Beamion LUNG-3 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Zongertinib; Pembrolizumab; Atezolizumab; Durvalumab; Nivolumab
- Arms
- Zongertinib treatment arm · Experimental
- Standard of Care (SoC) treatment arm · Active comparator
- Enrollment
- 400 (estimated)
- Primary outcomes
- Disease-free survival (DFS) by investigator's assessment
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 16, 2026
- Primary completion
- Feb 26, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT07195695 · updated Nov 2, 2026